Lantheus' blood pool agent lights up your life
Ablavar, the only commercially available blood pool MR contrast agent, lights up vasculature in this steady-state MR angiogram.
Ablavar, the only commercially available blood pool MR contrast agent, lights up vasculature in this steady-state MR angiogram. The agent entered the U.S. market early this year under the auspices of Lantheus Medical, a provider of ultrasound and nuclear medicine imaging agents. A different company, Epix Pharmaceuticals, had developed the agent, however, under the name Vasovist, and won FDA approval in December 2008 after a long struggle with American regulators.
Epix sold the U.S., Canadian, and Australian rights to market the agent to Lantheus in April 2008 for $28 million in a futile attempt to stay afloat after the company had switched its focus to the development of therapeutic drugs. Epix declared bankruptcy a year ago.
Its unique injectable MR angiography agent is approved by the FDA to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, producing high-resolution images with a single dose. Ablavar's albumin-binding properties allow the agent to persist in circulation for an extended time, illustrating vascular anomalies in both dynamic (first-pass) and steady-state imaging.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
